Repeated regulatory woes for SCM Pharma have left the U.K. contract manufacturer unable to afford its necessary upgrades, forcing Shire, its largest customer, to step in and take over.
Contract developer Almac has earmarked £54 million ($90 million) to expand in its native Northern Ireland, planning to add 348 jobs over 5 years.
WuXi PharmaTech, China's largest CRO, boosted its revenue by 14.8% in the second quarter, as banner growth in its contract manufacturing business helped the company expand its global reach.
Cubist Pharmaceuticals is recalling 100 lots of its banner antibiotic Cubicin after problems with a contract manufacturer, its third such issue in 12 months.
CRO Venn Life Sciences is spreading its reach around Europe through M&A, buying up a French outsourcer to bolster its abilities in data management.
CRO giant Icon continued its steady progress with another double-digit quarter of sales growth, piling up revenue with hopes of clearing $1.5 billion this year.
Charles River Laboratories is dialing up its expectations for the year after some M&A padded its second-quarter results, riding a 16.5% boost in sales.
Quintiles has signed a deal with a Roche diagnostics subsidiary to offer cancer screenings in China, looking to capitalize on the growing market for clinical trials in the country.
Parexel International posted an 11.8% revenue increase in its just-concluded fiscal year, posting record sales and forecasting another banner year.
Belgian medical device CRO Genae has landed in London, giving the fast-growing company a presence in the U.K. as it stretches its reach across Europe.
Pfizer and Roche are the latest pharma heavyweights to join Icon's consortium of drugmakers working to flesh out new technology for adaptive clinical trials, allowing study sponsors to react to results in real time and maximize efficacy.
Columbia Laboratories has struck a deal with CRO XenoGesis to team up on preclinical research, pooling their resources to offer tandem early-phase services.
Covance posted a strong revenue performance in the second quarter thanks to better-than-expected results from its early-stage development segment, but the CRO is inching back its full-year expectations to account for some outgoing assets.
Quintiles hit the $1 billion revenue mark for a third straight quarter, dialing up its full-year guidance as it expands its share of the global outsourcing market.
Catalent came through with the biggest life sciences IPO of what's shaping up to be a record year, pulling in $871.3 million in a blockbuster Wall Street debut.
Horizon Discovery, which makes its money providing development expertise to drugmakers, has signed a deal with Otsuka Pharmaceutical to apply its technology to some early-phase treatments.
Maryland's ABL has struck a deal to buy a majority stake in Platine Pharma Services, a French contract R&D organization that specializes in substances that provoke an immune response.
Global CRO Icon has deepened its longstanding relationship with Cambridge University, agreeing to lead a class on pricing and market access for new drugs.
TransCelerate BioPharma, a nonprofit run by 19 of the world's largest drugmakers, formed two years ago to help Big Pharma share resources and stop wasting time and money on noncompetitive work. Now, the group is looking to create a novel platform to standardize how clinical trial sites communicate with sponsors, choosing contractor Cognizant to develop it.
The CRO unit of nonprofit researcher SRI International has paired up with NIH's National Institute of Allergy and Infectious Diseases, signing a $49 million contract to handle preclinical work on potential treatments for HIV.